Updated: Jun 10, 2009
Optic nerve glioma (also known as optic pathway glioma) is the most common primary neoplasm of the optic nerve. Along with reducing visual acuity in the affected eye, the tumor sometimes produces additional symptoms as it grows. A low-grade form of this neoplasm, benign optic glioma, occurs most often in pediatric patients. Another form, aggressive glioma, is most common in adults; it is frequently fatal, even with treatment.1
Many children with optic nerve glioma are also known to have neurofibromatosis type 1 (NF-1) or, in some cases, hybrid phakomatosis.4
The World Health Organization classifies optic nerve gliomas as grade I astrocytomas (pilocytic astrocytomas) because they are slow growing and tend not to metastasize. Development of optic nerve gliomas occurs in stages, from generalized hyperplasia of glial cells in the nerve to complete disorganization with loss of neural landmarks in the nerve and nerve sheath. A reactive meningeal hyperplasia may be incited, making optic nerve glioma difficult to distinguish from a perioptic meningioma. It is unclear which glial cells give rise to benign optic glioma.
From 10 to 38% of pediatric patients with optic nerve glioma have NF-1; conversely, 15-40% of children with NF-1 have optic nerve glioma. Bilateral optic nerve gliomas are almost pathognomonic for NF-1.5
In the aggressive form of the disease, the glioma is either an anaplastic astrocytoma or a glioblastoma multiforme, arising from abnormal astrocytes. Prominent features of this neoplasm include nuclear pleomorphism, numerous mitoses, and vascular endothelial proliferation.
Benign optic glioma grows relatively slowly, if at all, over extended periods. However, some lesions can progress, causing visual impairment, so ongoing follow-up has been recommended.8
Twenty percent of optic gliomas that extend to the optic chiasm or beyond, into the optic radiations, demonstrate a more aggressive course.
Local surgical therapy for large lesions may cause significant morbidity, including hypothalamic dysfunction. Stereotactic radiation or gamma-knife therapy also can produce complications, including decreased visual acuity, radiation-induced optic neuritis, and ophthalmic artery vasculopathy.
Despite aggressive radiation, chemotherapeutic, or surgical treatment, aggressive glioma is an almost uniformly fatal disease.
There is no distinct racial predilection to sporadic optic nerve glioma. Benign optic glioma has the same distribution as NF-1.
In pediatric patients, there is a slight female predominance, whereas in adult patients, the opposite is true.6
In the pediatric population, the median patient age is 5 years, with 80% of patients presenting before age 15.6
In adult patients, the age ranges from 22-79 years, with a mean age of 52 years.7
The optic nerve is divided into 4 parts: (1) intraocular, (2) intraorbital, (3) intracanalicular, and (4) intracranial. Within the orbit, the nerve usually is approximately 5 mm in diameter and is surrounded by fat. The intracanalicular portion passes through the lesser wing of the sphenoid and is surrounded by a muscular cone. The cerebrospinal fluid (CSF) of the subarachnoid space surrounding the nerve is contiguous with the CSF of the intracranial compartment.
In 66% of NF-1 patients with optic nerve glioma, the growth involves the intraorbital optic nerve. In 10-20%, the tumor is confined to the orbit, with the remainder of these patients showing involvement of the intracranial compartment. In the absence of NF-1, the optic chiasm is most commonly involved, as is, less often, the intraorbital optic nerve.9 Optic nerve glioma may involve various portions of the retrobulbar visual pathway, including the optic nerve, chiasm, tracts, and radiations. Malignant lesions can invade the hypothalamus, basal ganglia, and internal capsule directly, or they may spread to the leptomeninges or subpial surfaces.
In most young patients with optic glioma, the presenting symptom is painless proptosis. Optic atrophy is common, as is reduced visual acuity, although the latter may be a late symptom. A large lesion may compress the optic chiasm, causing nystagmus or other symptoms. Hypothalamic symptoms, such as changes in appetite or sleep, also may occur. Massive lesions may compress the third ventricle, resulting in obstructive hydrocephalus accompanied by headache, nausea, and vomiting.10,11
In adult patients, bilateral vision loss is a common early finding because most lesions involve the optic chiasm.
When the diagnosis is in question, the presence of an intraconal mass can often be detected through CT scanning.
MRI, however, is the preferred method for definitive evaluation of optic nerve glioma. Both the intraorbital lesion and its intracranial extent can be effectively characterized through MRI. When evaluating the orbit, gadolinium-enhanced T1-weighted images with fat saturation can define the extent of aggressive glioma. Intracranially, MRI allows better evaluation of the optic nerve, chiasm, tracts, geniculate body, and optic radiations than does CT.12,13,14
Gadolinium-based contrast agents (gadopentetate dimeglumine [Magnevist], gadobenate dimeglumine [MultiHance], gadodiamide [Omniscan], gadoversetamide [OptiMARK], gadoteridol [ProHance]) have been linked to the development of nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy (NFD). For more information, see the eMedicine topic Nephrogenic Fibrosing Dermopathy. The disease has occurred in patients with moderate to end-stage renal disease after being given a gadolinium-based contrast agent to enhance MRI or MRA scans.
NSF/NFD is a debilitating and sometimes fatal disease. Characteristics include red or dark patches on the skin; burning, itching, swelling, hardening, and tightening of the skin; yellow spots on the whites of the eyes; joint stiffness with trouble moving or straightening the arms, hands, legs, or feet; pain deep in the hip bones or ribs; and muscle weakness. For more information, see the FDA Public Health Advisory or Medscape.
Although MRI may reveal even subtle lesions of the optic nerve, CT scanning can detect a subtle erosion or expansion of the optic canal. In addition, fine calcification, which may help to identify a lesion as a meningioma rather than a glioma, is visualized best through CT scanning.
Optic Neuritis
Retinoblastoma
Optic nerve meningioma
Lymphoma, soft tissue
Optic nerve sheath ectasia
The diagnosis may be made with a high degree of confidence when the lesion involves the optic chiasm and retrochiasmatic optic pathway.
When confined exclusively to the orbit, the lesion may mimic optic neuritis or optic nerve meningioma; in this setting and in most instances, MRI is a better diagnostic tool than is CT scanning.
CT scanning is the better modality for identifying uncommon meningioma with flecks of calcification, which are rare in optic nerve glioma.
False-positive results can occur because of unilateral optic nerve enhancement or other unilateral disorders, such as optic meningioma, vascular lesions, neuritis, pseudotumor, and sarcoidosis. In addition, subtle nerve enhancement occasionally may develop in normal individuals.
Improper examination techniques, including failure to administer contrast or obtain thin sections, can lead to a false-negative diagnosis.
Patients without NF-1 demonstrate cystic components more commonly at T2 -weighted imaging.9
The diagnosis may be made with a high degree of confidence when the lesion involves the optic chiasm and retrochiasmatic optic pathway.
When confined exclusively to the orbit, the lesion may mimic optic neuritis, pseudotumor, lymphoma, or optic nerve meningioma. Classically, meningioma, the primary differential diagnostic consideration, is characterized by the "tram-track" sign, with enhancement of the periphery of the nerve–optic sheath unit. On the other hand, enhancement in optic nerve glioma is more uniform. Isolated enlargement of the optic nerve sheath also may present diagnostic difficulty; however, this enlargement can usually be distinguished by its signal characteristics, which follow fluid signal on all MRI pulse sequences.
In most instances, including those described above, the diagnosis can be made with greater confidence using MRI than it can with CT scanning.
A false-positive diagnosis can occur as a result of unilateral optic nerve enhancement or other unilateral disorders, such as optic meningioma, vascular lesions, neuritis, pseudotumor, lymphoma, and sarcoidosis. In addition, subtle nerve enhancement occasionally may develop in normal individuals.
Improper examination techniques, including failure to administer contrast, use fat saturation, or obtain thin sections, can result in a false-negative diagnosis.
At present, no radiologic intervention techniques are used to treat optic nerve glioma.15
Wilhelm H. Primary optic nerve tumours. Curr Opin Neurol. Feb 2009;22(1):11-8. [Medline].
Aoki S, Barkovich AJ, Nishimura K, et al. Neurofibromatosis types 1 and 2: cranial MR findings. Radiology. Aug 1989;172(2):527-34. [Medline].
Hendrix LE, Kneeland JB, Haughton VM, et al. MR imaging of optic nerve lesions: value of gadopentetate dimeglumine and fat-suppression technique. AJNR Am J Neuroradiol. Jul-Aug 1990;11(4):749-54. [Medline].
Messori A, Salvolini U. Hybrid phakomatosis: from initial CT observation to molecular studies. AJNR Am J Neuroradiol. Aug 2004;25(7):1297-8.
Listernick R, Charrow J, Greenwald MJ, et al. Optic gliomas in children with neurofibromatosis type 1. J Pediatr. May 1989;114(5):788-92. [Medline].
Hollander MD, FitzPatrick M, O''Connor SG, et al. Optic gliomas. Radiol Clin North Am. Jan 1999;37(1):59-71, ix. [Medline].
Millar WS, Tartaglino LM, Sergott RC, et al. MR of malignant optic glioma of adulthood. AJNR Am J Neuroradiol. Sep 1995;16(8):1673-6. [Medline].
Thiagalingam S, Flaherty M, Billson F. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology. Mar 2004;111(3):568-77. [Medline].
Kornreich L, Blaser S, Schwarz M, et al. Optic pathway glioma: correlation of imaging findings with the presence of neurofibromatosis. AJNR Am J Neuroradiol. Nov-Dec 2001;22(10):1963-9. [Medline].
Tumialan LM, Dhall SS, Biousse V. Optic nerve glioma and optic neuritis mimicking one another: case report. Neurosurgery. Jul 2005;57(1):E190; discussion E190.
Taylor T, Jaspan T, Milano G, Gregson R, Parker T, Ritzmann T, et al. Radiological classification of optic pathway gliomas: experience of a modified functional classification system. Br J Radiol. Oct 2008;81(970):761-6. [Medline].
Forte R, Cennamo G, Breve MA. Three-Dimensional Ultrasound of Ophthalmic Pathologies. Ophthalmologica. Jan 31 2009;223(3):183-187. [Medline].
Walrath JD, Engelbert M, Kazim M. Magnetic resonance imaging evidence of optic nerve glioma progression into and beyond the optic chiasm. Ophthal Plast Reconstr Surg. Nov-Dec 2008;24(6):473-5. [Medline].
Buffa A, Vannelli S, Peretta P. [NF1 and gliomas: the importance of the MRI]. Minerva Pediatr. Apr 2008;60(2):259-60. [Medline].
Kwon Y, Bae JS, Kim JM. Visual changes after gamma knife surgery for optic nerve tumors. Report of three cases. J Neurosurg. Jan 2005;102 Suppl:143-6.
optic nerve glioma, optic pathway glioma, optic glioma, neurofibromatosis, neurofibromatosis type 1, NF-1, neurofibromatosis 1, von Recklinghausen disease, optic nerve disease, hybrid phakomatosis
Richard J Woodcock Jr, MD, Consulting Radiologist, Atlanta Radiology Consultants, LLC; Consulting Radiologist and MRI Director, St Joseph's Hospital
Richard J Woodcock Jr, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Radiology, American Medical Association, American Roentgen Ray Society, American Society of Neuroradiology, Phi Beta Kappa, and Radiological Society of North America
Disclosure: Nothing to disclose.
Barton F Branstetter IV, MD, Associate Professor of Radiology, Otolaryngology, and Biomedical Informatics, University of Pittsburgh; Director of Head and Neck Imaging, Clinical Director of Neuroradiology, Department of Radiology, Division of Neuroradiology, University of Pittsburgh Medical Center
Barton F Branstetter IV, MD is a member of the following medical societies: American College of Radiology, American Medical Association, American Roentgen Ray Society, American Society of Neuroradiology, Pennsylvania Medical Society, and Radiological Society of North America
Disclosure: Nothing to disclose.
Bernard D Coombs, MB, ChB, PhD, Consulting Staff, Department of Specialist Rehabilitation Services, Hutt Valley District Health Board, New Zealand
Disclosure: Nothing to disclose.
C Douglas Phillips, MD, Director of Head and Neck Imaging, Division of Neuroradiology, Weill Medical College of Cornell University/New York Presbyterian Hospital
C Douglas Phillips, MD is a member of the following medical societies: American College of Radiology, American Medical Association, American Society of Head and Neck Radiology, American Society of Neuroradiology, Association of University Radiologists, and Radiological Society of North America
Disclosure: Nothing to disclose.
Robert M Krasny, MD, Consulting Staff, Department of Radiology, Resolution Imaging Medical Corporation
Robert M Krasny, MD is a member of the following medical societies: American Roentgen Ray Society and Radiological Society of North America
Disclosure: Nothing to disclose.
Lawrence M Davis, MD, Assistant Professor of Diagnostic Imaging (Clinical), Department of Diagnostic Imaging, Warren Alpert Medical School at Brown University
Lawrence M Davis, MD is a member of the following medical societies: American College of Radiology, American Roentgen Ray Society, American Society of Neuroradiology, Radiological Society of North America, and Rhode Island Medical Society
Disclosure: Nothing to disclose.
Related eMedicine topics
Neurofibromatosis Type 1 (from Radiology)
Neurofibromatosis, Type 1 (from Neurology)
Optic Neuropathy, Compressive
Sudden Visual Loss (from Neurology)
Sudden Visual Loss (from Ophthalmology)
Clinical guidelines
Eye Examination in Infants, Children, and Young Adults by Pediatricians
Neurofibromatosis Type 1 in Genetic Counseling Practice: Recommendations of the National Society of Genetic Counselors
Clinical studies
Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas
Trial to Evaluate the Safety of Lovastatin in Adults With Neurofibromatosis Type I (NF1)
© 1994-
by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)